According to Fortune Business Insights, the global biomarkers market size was valued at USD 86.95 billion in 2025. The market is projected to grow from USD 97.50 billion in 2026 to USD 217.58 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 12.20% during the forecast period. North America dominated the global market, accounting for 36.93% of the market share in 2025.
Biomarkers are measurable biological indicators that provide information about physiological processes, disease conditions, and responses to medical treatments. They can be identified through blood, tissue, urine, genetic material, and other biological samples. Biomarkers are widely used in disease diagnosis, risk assessment, prognosis, drug discovery, and treatment monitoring.
The increasing prevalence of chronic diseases, rising demand for personalized medicine, and advancements in molecular diagnostics are supporting market growth. Pharmaceutical and biotechnology companies are also investing in biomarker research to improve clinical trial efficiency and develop targeted therapies.
Market Size and Forecast
- 2025 Market Size: USD 86.95 billion
- 2026 Market Size: USD 97.50 billion
- 2034 Forecast Market Size: USD 217.58 billion
- CAGR (2026–2034): 12.20%
The market is expected to expand as healthcare providers increasingly adopt biomarker-based diagnostic methods and pharmaceutical companies integrate biomarkers into drug development. Advances in genomics, proteomics, and molecular testing are further supporting market development.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biomarkers-market-102173
Key Market Growth Drivers
Rising Prevalence of Chronic Diseases
The growing incidence of cancer, cardiovascular disorders, neurological conditions, and other chronic diseases is increasing demand for reliable diagnostic tools. Biomarkers help clinicians identify disease-related biological changes, assess disease progression, and evaluate responses to treatment.
Early detection is particularly important in oncology and cardiovascular care, where timely diagnosis can influence treatment decisions. The increasing use of biomarker-based testing is therefore contributing to market expansion.
Growing Demand for Personalized Medicine
Personalized medicine uses patient-specific biological information to guide diagnosis and treatment selection. Biomarkers help healthcare professionals identify patients who are more likely to benefit from particular therapies and monitor treatment effectiveness.
The growing adoption of precision oncology and targeted therapies is encouraging pharmaceutical companies to develop companion diagnostics and identify predictive biomarkers. These applications are increasing the importance of biomarker research in clinical practice.
Advancements in Drug Discovery and Development
Biomarkers play an important role in pharmaceutical research by helping researchers identify therapeutic targets, evaluate drug activity, and assess safety during clinical development. Their use can support patient selection and improve the interpretation of clinical trial results.
Advances in next-generation sequencing, mass spectrometry, and molecular analysis are enabling researchers to discover and validate new biomarkers. Increasing investment in biotechnology research is expected to create additional opportunities for market participants.
Market Segmentation
According to Fortune Business Insights, the biomarkers market is segmented by indication and end-user.
By Indication: The market includes oncology, cardiology, neurology, and other indications. Oncology is projected to account for 49.44% of the market in 2026, supported by the growing use of biomarkers in cancer detection, prognosis, treatment selection, and monitoring. Cardiology biomarkers help diagnose cardiovascular conditions, while neurological biomarkers support research into neurodegenerative diseases and related disorders.
By End-User: Major end-users include pharmaceutical and biotechnology companies, diagnostics and research laboratories, hospitals and specialty clinics, and other organizations. Diagnostics and research laboratories are projected to hold a 52.89% market share in 2026. Their leading position reflects demand for biomarker testing, clinical research, assay development, and disease investigation. Pharmaceutical and biotechnology companies also contribute significantly through investments in drug discovery and biomarker validation.
Regional Market Insights
North America
North America dominated the market with revenue of USD 32.12 billion in 2025 and is projected to reach USD 35.87 billion in 2026. Advanced healthcare infrastructure, substantial biotechnology investments, and increasing adoption of personalized medicine support regional growth. The U.S. market is projected to reach USD 31.17 billion in 2026.
Europe
Europe generated USD 24.75 billion in 2025 and is expected to reach USD 27.84 billion in 2026. Established research institutions, advanced diagnostic technologies, and increasing investment in precision medicine are supporting market development. Germany and the U.K. remain important markets for biomarker research and clinical applications.
Asia Pacific
Asia Pacific accounted for USD 22.31 billion in 2025 and is projected to reach USD 25.23 billion in 2026. Rising chronic disease prevalence, expanding healthcare infrastructure, and increasing investments in biotechnology are supporting regional growth. Japan's market is projected to reach USD 7.34 billion in 2026, while China's market is expected to reach USD 6.66 billion.
Key Market Challenges
The biomarkers market faces challenges related to high research and development costs, complex validation procedures, and regulatory requirements. Developing reliable biomarkers requires extensive clinical studies and testing to establish accuracy, reproducibility, and clinical usefulness.
Differences in biological characteristics among patient populations can also affect biomarker performance. Additionally, limited access to advanced testing infrastructure in some regions may restrict adoption. Addressing these challenges through standardized testing methods and improved analytical technologies will be essential for market growth.
Competitive Landscape
The global biomarkers market includes established diagnostics companies, biotechnology firms, and specialized research providers. Key players identified by Fortune Business Insights include F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., CENTOGENE N.V., Axon Medchem, Sino Biological Inc., BioVision Inc., and Myriad RBM.
Companies are focusing on product innovation, strategic collaborations, biomarker discovery platforms, and companion diagnostic development to strengthen their competitive positions. Investments in advanced molecular testing and precision medicine are creating opportunities across clinical diagnostics and pharmaceutical research.
Conclusion
The global biomarkers market is projected to grow from USD 86.95 billion in 2025 to USD 217.58 billion by 2034. Increasing demand for personalized medicine, rising chronic disease prevalence, and advancements in diagnostic technologies are expected to drive expansion. Although high development costs and validation requirements remain challenges, continued innovation in biomarker discovery and clinical applications is likely to create substantial opportunities for the industry.
Comments